Immune cells (killer T cells) present in the spinal fluid are attacking the Epstein-Barr virus (EBV) in multiple sclerosis (MS) patients, showing that EBV may trigger MS disease.
Bimekizumab, a humanised monoclonal antibody, is the first and only dual inhibitor of IL-17A and IL-17F, two pro-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results